Sihuan Pharmaceutical Holdings Group (SZSC:460) - Cotización, noticias y análisis

Resumen de acción 460

460 fundamental analysis
Snowflake Score
Valuation	3/6
Future Growth	5/6
Past Performance	0/6
Financial Health	3/6
Dividends	0/6

Recompensas

Cotiza un 26.7% por debajo de nuestra estimación de su valor justo

Se prevé un crecimiento anual de los beneficios de 117.68%

Análisis de riesgos

No se han detectado riesgos en 460 a partir de nuestros controles de riesgos.

Competidores de Sihuan Pharmaceutical Holdings Group Ltd.

Shanghai Fudan-Zhangjiang Bio-PharmaceuticalLtd

SEHK:1349

HK$5.7b

Consun Pharmaceutical Group

SEHK:1681

HK$5.3b

China Shineway Pharmaceutical Group

SEHK:2877

HK$6.2b

Tong Ren Tang Technologies

SEHK:1666

HK$7.1b

Historial de precios y rendimiento

Summary of all time highs, changes and price drops for Sihuan Pharmaceutical Holdings Group
Historical stock prices
Current Share Price	HK$0.52
52 Week High	HK$0.80
52 Week Low	HK$0.49
Beta	0.60
1 Month Change	-17.46%
3 Month Change	-8.77%
1 Year Change	-29.73%
3 Year Change	-84.52%
5 Year Change	-68.10%
Change since IPO	-75.24%

Noticias y actualizaciones recientes

Recent updates

Rentabilidad de los accionistas

	460	HK Pharmaceuticals	Mercado HK
7D	-3.7%	4.0%	1.1%
1Y	-29.7%	-3.8%	-0.5%

Rentabilidad vs. Industria: 460 obtuvo unos resultados inferiores a los del sector Hong Kong Pharmaceuticals , que el año pasado arrojó un rendimiento del -15.9%.

Rentabilidad vs. Mercado: 460 obtuvo unos resultados inferiores a los del mercado Hong Kong, que fue del -10.1% el año pasado.

Volatilidad de los precios

Is 460's price volatile compared to industry and market?
460 volatility
460 Average Weekly Movement	6.8%
Pharmaceuticals Industry Average Movement	5.7%
Market Average Movement	7.3%
10% most volatile stocks in HK Market	15.7%
10% least volatile stocks in HK Market	3.7%

Precio estable de las acciones: 460 no ha tenido una volatilidad de precios significativa en los últimos 3 meses.

Volatilidad a lo largo del tiempo: La volatilidad semanal de 460 (7%) se ha mantenido estable durante el año pasado.

Acerca de la empresa

Fundada	Empleados	CEO	Página web
2001	2,872	Weicheng Guo	www.sihuanpharm.com

Sihuan Pharmaceutical Holdings Group Ltd., sociedad de cartera de inversiones, se dedica a la investigación y desarrollo, fabricación, comercialización y venta de productos farmacéuticos y médico-estéticos en la República Popular China. La empresa opera a través de tres segmentos: Productos de Estética Médica, Medicina Innovadora y Otros Medicamentos, y Medicamentos Genéricos. Ofrece soluciones integrales de estética médica no invasivas o mínimamente invasivas de relleno, modelado, apoyo, suplementación, dispositivos optoelectrónicos, escultura corporal, cuidado de la piel y otros.

Resumen de fundamentos de Sihuan Pharmaceutical Holdings Group Ltd.

¿Cómo se comparan los beneficios e ingresos de Sihuan Pharmaceutical Holdings Group con su capitalización de mercado?
Estadísticas fundamentales de 460
Capitalización bursátil	HK$4.83b
Beneficios(TTM)	-HK$58.23m
Ingresos (TTM)	HK$2.01b

2.4x

Ratio precio-ventas (PS)

-82.9x

Ratio precio-beneficio (PE)

¿Está 460 sobrevalorada?

Ver valor justo y análisis de valoración

Beneficios e Ingresos

Estadísticas clave de rentabilidad del último informe de resultados (TTM)
Cuenta de resultados (TTM) de 460
Ingresos	CN¥1.86b
Coste de los ingresos	CN¥564.90m
Beneficio bruto	CN¥1.30b
Otros gastos	CN¥1.35b
Beneficios	-CN¥54.02m

Últimos beneficios comunicados

Dec 31, 2023

Próxima fecha de beneficios

n/a

Beneficios por acción (BPA)	-0.0058
Margen bruto	69.64%
Margen de beneficio neto	-2.90%
Ratio deuda/patrimonio	22.9%

¿Cómo se ha desempeñado 460 a largo plazo?

Ver rendimiento histórico y comparativa

Resumen de acción 460

Recompensas

Análisis de riesgos

Competidores de Sihuan Pharmaceutical Holdings Group Ltd.

SEHK:1349

HK$5.7b

SEHK:1681

HK$5.3b

SEHK:2877

HK$6.2b

SEHK:1666

HK$7.1b

Historial de precios y rendimiento

Noticias y actualizaciones recientes

Now 21% undervalued after recent price drop

Full year 2023 earnings released: CN¥0.006 loss per share (vs CN¥0.21 loss in FY 2022)

Sihuan Pharmaceutical Holdings Group Ltd., Annual General Meeting, Jun 07, 2024

Full year 2023 earnings released: CN¥0.006 loss per share (vs CN¥0.21 loss in FY 2022)

Sihuan Pharmaceutical Holdings Group Ltd. Receives Registration Approval from National Medical Products Administration for Proline Janagliflozin Tablets

Now 20% undervalued after recent price drop

Recent updates

Now 21% undervalued after recent price drop

Full year 2023 earnings released: CN¥0.006 loss per share (vs CN¥0.21 loss in FY 2022)

Sihuan Pharmaceutical Holdings Group Ltd., Annual General Meeting, Jun 07, 2024

Full year 2023 earnings released: CN¥0.006 loss per share (vs CN¥0.21 loss in FY 2022)

Sihuan Pharmaceutical Holdings Group Ltd. Receives Registration Approval from National Medical Products Administration for Proline Janagliflozin Tablets

Now 20% undervalued after recent price drop

Sihuan Pharmaceutical Holdings Group Ltd. Obtains Drug Registration Approval from the National Medical Products Administration of the People's Republic of China for the Treatment of Diabetes

National Medical Products Administration Approves IND Application of Insulin Degludec and Liraglutide Injection, Developed by Huisheng Biopharmaceutical

First half 2023 earnings released: CN¥0.005 loss per share (vs CN¥0.004 profit in 1H 2022)

Sihuan Pharmaceutical Holdings Group Ltd. to Report First Half, 2023 Results on Aug 29, 2023

Sihuan Pharmaceutical Holdings Group Ltd. Announces Huisheng Biopharmaceutical's Drug Semaglutide Injection Obtained Approval for Clinical Trial

Sihuan Pharmaceutical Holdings Group Ltd. Announces Approval of Phase II Clinical Trial Application of Birociclib by the Center for Drug Evaluation of the National Medical Products Administration of the People's Republic of China

Sihuan Pharmaceutical Holdings Group Ltd. Obtains Drug Registration Approval from the National Medical Products Administration

Upcoming dividend of HK$0.037 per share at 9.7% yield

Full year 2022 earnings released: CN¥0.21 loss per share (vs CN¥0.044 profit in FY 2021)

Sihuan Pharmaceutical Holdings Group Ltd. Provides Consolidated Earnings Guidance for the Year Ended 31 December 2022

Less than half of directors are independent

Sihuan Pharmaceutical Holdings Group Ltd. Announces Management Changes

Upcoming dividend of HK$0.037 per share

Sihuan Pharmaceutical Holdings Group Ltd. Declares Special Cash Dividend for the Six Months Ended 30 June 2022, Payable on or Around 13 October 2022

First half 2022 earnings released: EPS: CN¥0.004 (vs CN¥0.065 in 1H 2021)

Sihuan Pharmaceutical Holdings Group Ltd. to Report First Half, 2022 Results on Aug 30, 2022

Sihuan Pharmaceutical Holdings Group Ltd. Provides Earnings Guidance for the Six Months Ended 30 June 2022

Sihuan Pharmaceutical Holdings Group Ltd. Announces Acceptance of Application for Marketing of Xuanzhu Biopharm\U0027s Drug Fulvestrant Injection by Nmpa of China

Upcoming dividend of HK$0.13 per share

Investor sentiment deteriorated over the past week

Less than half of directors are independent

Sihuan Pharmaceutical Obtains Class III Medical Device Registration Certificate from NMPA for Exclusively Distributed Hyaluronic Acid Persnica

Now 20% undervalued

Full year 2021 earnings released: EPS: CN¥0.044 (vs CN¥0.054 in FY 2020)

Sihuan Pharmaceutical Holdings Group Ltd., Annual General Meeting, May 24, 2022

Sihuan Pharmaceutical Holdings Group Ltd. Announces Ordinary Final Cash Dividend for the Year Ended December 31, 2021, Payable on June 14, 2022

Investor sentiment deteriorated over the past week

Now 25% undervalued after recent price drop

Sihuan Pharmaceutical Holdings Group Ltd. Announces First Class I Macromolecule Innovative Drug Her2 Bispecific Antibody Xzp-Km257 Was Approves for Clinical Trails

Investor sentiment improved over the past week

National Medical Products Administration Accepts Biologics License Application of Insulin Aspart Injection, Insulin Aspart 30 Injection and Insulin Aspart 50 Injection of Jilin Huisheng Biopharmaceutical Co., Ltd

Now 22% undervalued after recent price drop

Sihuan Pharmaceutical Holdings Group Ltd. Announces Medical Device Registration Certificate Obtained for Medical Skin Care Gel and Repair Gel

Sihuan Pharmaceutical Holdings Group Ltd. Announces Fondaparinux Sodium Injection Obtained Manufacture Approval

Investor sentiment deteriorated over the past week

First half 2021 earnings released: EPS CN¥0.065 (vs CN¥0.018 in 1H 2020)

Non-Executive Director Jin-ha Kim has left the company

Investor sentiment deteriorated over the past week

Upcoming dividend of HK$0.016 per share

Sihuan Pharmaceutical Holdings Group Ltd. Announces Obtains Drug Registration Approval in Relation to Caspofungin Acetate for Injection

Sihuan Pharmaceutical Holdings Group Ltd. Recommends Final Cash Dividend for the Year Ended December 31, 2020, Payable on or Around July 15, 2021

Investor sentiment improved over the past week

Investor sentiment improved over the past week

Sihuan Pharmaceutical Holdings Group Ltd. Recommends Two Special Cash Dividends

Full year 2020 earnings released: EPS CN¥0.054 (vs CN¥0.29 loss in FY 2019)

Sihuan Pharmaceutical Holdings Group Ltd. to Report Fiscal Year 2020 Results on Mar 23, 2021

New 90-day high: HK$2.68

Sihuan Pharmaceutical Holdings Group Ltd. Announces Selection of its Pantoprazole Sodium Injection (Panzuoer® 40mg per unit) and Ibuprofen Injection (Falanfen® 4ml: 0.4g, Tenaan® 8ml: 0.8g) in the Fourth Batch of National Drug Centralized Procurement

Sihuan Pharmaceutical Holdings Group Ltd. Announces Cinepazide Maleate Injection Obtain Approval from the National Medical Products Administration

New 90-day high: HK$1.32

Upcoming Dividend of HK$0.035 Per Share

Sihuan Pharmaceutical Holdings Group Ltd.(SEHK:460) dropped from FTSE All-World Index (USD)

First half earnings released